Objective-Human pregnancy that courses with maternal supraphysiological hypercholesterolemia (MSPH) correlates with atherosclerotic lesions in fetal arteries. It is known that hypercholesterolemia associates with endothelial dysfunction in adults, a phenomenon where nitric oxide (NO) and arginase are involved. However, nothing is reported on potential alterations in the fetoplacental endothelial function in MSPH. The aim of this study was to determine whether MSPH alters fetal vascular reactivity via endothelial arginase/urea and l-arginine transport/NO signaling pathways. Approach and Results-Total cholesterol <280 mg/dL was considered as maternal physiological hypercholesterolemia (n=46 women) and ≥280 mg/dL as MSPH (n=28 women). Maternal but not fetal total cholesterol and low-density lipoprotein-cholesterol levels were elevated in MSPH. Umbilical veins were used for vascular reactivity assays (wire myography), and primary cultures of umbilical vein endothelial cells to determine arginase, endothelial NO synthase (eNOS), and human cationic amino acid transporter 1 and human cationic amino acid transporter 2A/B expression and activity. MSPH reduced calcitonine gene-related peptide-umbilical vein relaxation and increased intima/media ratio (histochemistry), as well as reduced eNOS activity (l-citrulline synthesis from l-arginine, eNOS phosphorylation/dephosphorylation), but increased arginase activity and arginase II protein abundance. Arginase inhibition increased eNOS activity and l-arginine transport capacity without altering human cationic amino acid transporter 1 or human cationic amino acid transporter 2A/B protein abundance in maternal physiological hypercholesterolemia and MSPH. Conclusions-MSPH is a pathophysiological condition altering umbilical vein reactivity because of fetal endothelial dysfunction associated with arginase and eNOS signaling imbalance. We speculate that elevated maternal circulating cholesterol is a factor leading to fetal endothelial dysfunction, which could have serious consequences to the growing fetus. (Arterioscler Thromb Vasc Biol. 2013;33:2444-2453.) The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
H uman pregnancy courses with physiological increase of maternal blood total cholesterol (TCh). 1, 2 This phenomenon is referred to as maternal physiological hypercholesterolemia (MPH) in pregnancy and is considered an adaptive response to satisfy the increasing fetal lipids demand. 3, 4 Increase in maternal TCh over MPH levels is defined as maternal supraphysiological hypercholesterolemia (MSPH) in pregnancy. 4 Surprisingly, even when a strong correlation between maternal cholesterolemia before and during pregnancy and the size of atherosclerotic lesions in fetal arteries is documented, 5 MSPH effect on fetal endothelial function is unknown. 4, 6 It is noticeable that the total blood cholesterol in the newborn from pregnancies coursing with MSPH is reported as similar to that with MPH; however, a strong correlation between maternal and fetal cholesterol in the first two thirds of pregnancy is described. 5 Because MSPH associates with increased atherosclerosis in childhood, 5 and maternal cholesterol may reach the fetal circulation by crossing the placenta via membrane transporters, 7 MSPH is a pathological condition resulting in in uterus fetal programming of this and perhaps other diseases of childhood, and potentially in the adulthood, 4 and could well result in fetal endothelial dysfunction. Several factors lead to endothelial dysfunction, including elevated plasma cholesterol (ie, hypercholesterolemia). 8 Patients with hypercholesterolemia exhibit low nitric oxide (NO) bioavailability 8 and less efficient endothelial l-arginine uptake, 9 the substrate of NO synthases. Because NO synthesis depends on l-arginine uptake in human placenta endothelium, [10] [11] [12] [13] [14] [15] [16] [17] MSPH could result in altered l-arginine transport and NO synthesis, that is, the l-arginine/NO pathway, in fetal endothelium.
l-Arginine uptake occurs predominantly via the human cationic amino acid transporters (hCATs) family. 13 hCATs family includes ≥5 members, that is, hCAT-1, hCAT-2A, hCAT-2B, hCAT-3, and hCAT-4, 12, 13 of which the high-affinity, lowcapacity hCAT-1 is the main isoform expressed in human umbilical vein endothelial cells (HUVEC), 15, 16 a cell type exposed to oxygen-and nutrient-enriched blood (ie, arteriallike blood, reaching fetal circulation). 18 Interestingly, altered hCAT-1 activity could result in abnormal NO synthesis in HUVEC. 10, 11, 15, 17 Hypercholesterolemia also associates with reduced endothelial NO synthase (eNOS) activity paralleled by higher arginases expression and activity. 19, 20 l-Arginine is the substrate for arginase activity, thus competing with eNOS for this amino acid. 21 Furthermore, patients with hypercholesterolemia exhibit increased activity of endothelial arginase I and arginase II (ARGII) forms. 19, 22 However, the potential effect of MSPH on arginases activity and expression and its consequences in modulation of fetal endothelial function is unknown. 4, 6 Because endothelial dysfunction precedes hypercholesterolemia-associated atherosclerosis even without structural vascular abnormalities, 23 the hypothesis of this study was that MSPH will associate with fetal endothelial dysfunction where arginases will play crucial roles.
The results show that pregnant women with MSPH exhibit reduced umbilical vein dilation and eNOS activity, but higher hCAT-1 mediates l-arginine transport without changes in eNOS or hCAT-1 expression in HUVEC. Parallel assays show higher arginase activity and ARGII expression in MSPH. In addition, umbilical veins exhibit a higher intima/media ratio in MSPH. MSPH was associated with significantly higher TCh levels in the maternal plasma, compared with MPH, but was not associated with elevated TCh in the umbilical cord vein (ie, the fetal circulation). Thus, we suggest that MSPH could be a maternal pathological condition that associates with altered umbilical vein reactivity caused by fetal endothelial dysfunction. This could be a crucial mechanism accounting for the onset of the atherogenic process in the fetus from mothers with MSPH increasing the risk for an adverse fetal outcome and for the development of adulthood diseases.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Study Groups
With the exception of maternal weight, none of the other maternal or newborn variables changed during the third trimester compared with before pregnancy or first trimester of pregnancy (Table 1) . [24] [25] [26] [27] [28] [29] [30] 
Maternal and Newborn Plasma Lipids
Maternal blood TCh, high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), or very-low-density lipoprotein-cholesterol and triglycerides before pregnancy were similar in MPH ( Figure 1A ) and MSPH ( Figure 1B ). Maternal TCh was higher in the second and third trimester compared with first trimester of pregnancy or values before pregnancy in both conditions. HDL-C, LDL-C, and verylow-density lipoprotein-cholesterol levels were unaltered along pregnancy in MPH; however, LDL-C was higher in the third trimester compared with before pregnancy or first trimester in MSPH. The increase in maternal TCh in the second and third trimester from values in first trimester in MSPH was higher than changes in MPH. LDL-C level at third trimester was higher than before pregnancy and first trimester in MSPH, and the increase in MSPH was higher than that in MPH. Maternal triglyceride blood level in the third trimester was higher than values before pregnancy or at first trimester in MPH or in MSPH ( Figure 1C ). However, increase in maternal triglyceride was similar in MPH and in MSPH. TCh, HDL-C, and triglycerides levels in newborn umbilical blood were unaltered by MSPH ( Figure 1D ).
Umbilical Vein Morphology
Intima layer thickness was higher, but media thickness was unaltered in umbilical veins from MSPH compared with MPH ( Figure 2 ). Moreover, higher amplitude of projections of the internal elastic layer into the media from the intima is seen in MSPH compared with MPH. In none of the samples studied, CD68+ cells were found (not shown).
Umbilical Vein Reactivity
Calcitonine gene-related peptide (CGRP) caused a maximal dilation (D max ) of umbilical vein rings from MPH (D max =28±7%; Figure 3A ) that was higher than in vein rings from MSPH (D max =6±3%; Figure 3B ). The CGRP D max in MPH was unaltered by the arginases inhibitor S-(2-boronoethyl)-L-cysteine (BEC). However, the presence of BEC-increased CGRP dilation (D max =13±5%) in vein rings from MSPH. CGRP EC 50 was higher in MSPH compared with MPH ( Table 2) . Similar results were obtained in umbilical vein rings preconstricted with serotonin (not shown). BEC reduced the CGRP EC 50 in MPH and in MSPH, with MSPH EC 50 being around 1 order of magnitude lower compared with MPH. Inhibition of NOS activity with L N G -nitro-l-arginine methyl ester (L-NAME) caused a reduction in vein rings dilation in the absence of BEC; however, CGRP dilation was abolished in the presence of L-NAME+BEC in MPH and in MSPH. The NO donor sodium nitroprusside caused comparable dilation in veins from MPH and MSPH ( Figure 3C ).
Arginases and eNOS Protein Abundance
ARGII protein abundance was higher (1.6±0.1-fold) in MSPH compared with MPH; however, arginase I protein abundance was barely detected ( Figure 3D ). Arginase I and total eNOS ( Figure 3E ) protein abundance were unaltered by MSPH.
Arginase Activity
Cells from MSPH exhibit higher v i for overall arginase activity compared with MPH, and BEC blocked arginase activity in both cell types ( Figure 4A ; Table 3 ). BEC-inhibited overall arginase activity was also higher in MSPH compared with MPH ( Figure 4B ) and was semisaturable in both conditions ( Figure 4C ). Eadie-Hofstee plot of this data were biphasic ( Figure 4D ). Saturable BEC-inhibited arginase activity exhibits higher V max , without altering the apparent K m in MSPH compared with MPH ( Figure 4E ; Table 3 ) and Eadie-Hofstee plot was linear ( Figure 4F ).
NOS Activity
l-Citrulline formation in cells from MSPH was lower than MPH and inhibited by l-NAME ( Figure 5A ). BEC increased l-citrulline formation reaching similar values in MPH and in MSPH. L-NAME-inhibited l-citrulline formation was higher (1.6±0.2-fold) in MPH compared with MSPH ( Figure 5B ). NOS activity was higher in the presence of BEC reaching similar maximal values in both cell types, and NOS-increased activity was 1.9±0.3-fold in MSPH compared with MPH ( Figure 5B , inset). eNOS phosphorylation in Ser 1177 and Thr 495 relative to total eNOS was lower in MSPH than MPH ( Figure 5C ). eNOS phosphorylation in Ser 1177 and Thr 495 was increased in MPH, but Ser 1177 phosphorylation was increased and Thr 495 phosphorylation was decreased in cells from MSPH in the presence of BEC.
l-Arginine Transport l-Arginine uptake v i was higher (2.8±0.1-fold) in MSPH compared with MPH and increased by BEC reaching similar values in both conditions ( Figure 6A ). Overall l-arginine transport was semisaturable in MPH but saturable in MSPH in the absence of BEC ( Figure 6B ). BEC increased overall transport reaching comparable maximal transport values in MPH and in MSPH. Eadie-Hofstee plot of overall transport was biphasic in MPH but linear in MSPH in the absence of BEC; however, it was linear in MPH or MSPH in the presence of BEC ( Figure 6C ). Saturable l-arginine transport exhibited higher V max and V max /K m , with no significant changes in the apparent K m , in MSPH compared with MPH ( Figure 6D ; Table 3 ). Saturable transport data were linear in an Eadie-Hofstee plot ( Figure 6E ). Parallel assays show that neither hCAT-1 nor hCAT-2A/B protein abundance was altered in cells from MSPH compared with MPH ( Figure 6F ).
Discussion
This study shows that MSPH associates with umbilical vein endothelial dysfunction and altered umbilical vein reactivity compared with MPH. A higher maternal LDL-C, without changes in HDL-C or very-low-density lipoprotein-cholesterol, or triglycerides in MSPH was seen. However, newborns from MSPH exhibit normal levels of TCh, HDL-C, and triglycerides. MSPH reduced endothelium-derived NO-dependent dilation of umbilical vein rings and associated with higher intima/media ratio in umbilical veins compared with MPH. Arginase activity inhibition reversed MSPH effect on vein ring dilation. ARGII protein abundance and activity were increased, but eNOS activity was reduced in HUVEC from MSPH. MSPH and arginase inhibition also increased the V max /K m for l-arginine transport in MSPH, without changing hCAT-1 or hCAT2A/B protein abundance. Thus, MSPH results in human umbilical vein endothelial dysfunction likely because of an imbalance between eNOS and ARGII activity and expression. Furthermore, we identified a cut-off point at which risk of human umbilical vein endothelial dysfunction increases in pregnant women with MSPH. These findings suggest a potential mechanism that could be accounting for the reported atherogenic process in the fetus from mothers with MSPH 5 perhaps reflecting an in uterus fetal programming of this disease.
MSPH Cut-Off Point
In 28 of 74 pregnant women studied, we observed reduced reactivity of umbilical vein rings, increased umbilical vein intima/media ratio, as well as altered eNOS and ARGII activity, and l-arginine transport kinetics in HUVEC. All of these women had a TCh>280 mg/dL. We, therefore, defined MSPH as TCh≥280 mg/dL, that is, the level associated with vascular pathologies, and MPH as TCh<280 mg/dL. This level of maternal plasma TCh was established as the cut-off point for this study. This cut-off point is similar to TCh level in pregnant women showing increased oxidative stress in maternal and fetal blood, and homogenized placenta, and exhibit reduced maternal omental artery reactivity and altered composition of the fetal blood fatty acids. 31 Furthermore, increased early atherosclerosis markers, such as fatty streaks and lipid peroxidation, in human fetal aorta 5 or in 7-to 14-year-old children 32 born from mothers with TCh level over this cut-off point is reported. Because TCh, HDL-C, and triglyceride plasma levels were unaltered in newborns from women with MSPH, confirming previous observations, 33, 34 we speculate on the possibility that MSPH is a pathological condition of the mother coursing with altered human fetoplacental vasculature. A role for LDL-C is suggested in this phenomenon because its maternal plasma concentration was higher in MSPH compared with MPH and because LDL-C is transferred across the placenta. 18
Vascular Reactivity and ARGII
MSPH reduced umbilical vein dilation in response to the endothelium-dependent vasodilator CGRP. 28, 35 Because dilation caused by sodium nitroprusside (NO donor) was unaltered by MSPH, the umbilical vein endothelium rather than smooth muscle is likely altered. Thus, reduced CGRP sensitivity or reactivity of umbilical vein endothelium from MSPH is suggested. Interestingly, hypercholesterolemia associates with increased intima/media thickness in human carotid artery, which correlates with reduced brachial artery flow mediated dilation. 35, 36 Our results also show increased umbilical vein intima/media ratio in MSPH; thus, a well-preserved endothelium/smooth muscle structure is required for proper reactivity of these vessels. We did not identify CD68+ cells in these preparations suggesting that vascular dysfunction caused by MSPH is not dependent on the intimal recruitment of monocyte/macrophages and may, therefore, represent an initial step of atherogenic programming in fetal arteries. CGRP dilation in umbilical vein rings from MSPH was increased by BEC (arginase inhibitor), suggesting that arginase activity could limit CGRP dilation response in these vessels. However, because BEC did not restores CGRP dilation in vessel rings from MSPH to values in MPH, an alternative mechanism(s) than arginase activity in response to CGRP is likely in MSPH, including eNOS uncoupling or reduced bioavailability of the eNOS cofactor tetrahydrobiopterin. Because ARGII protein abundance in MSPH is ≈1.6-fold than in MPH, arginase activity (likely ARGII) will predominate over the effect of a change in ARGII expression in CGRP dilation in umbilical veins. The latter is feasible because BEC was assayed for 30 minutes in our study, and the reported endothelial ARGII protein half-life is ≈4 hours. 37 Thus, ARGII could play a role in umbilical vein reactivity in MSPH. The v i for arginase activity was higher in HUVEC from MSPH compared with MPH, and a comparable increase in V max /K m was seen. Thus, increased activity without changes in functional arginase or increased arginases protein abundance without changing V max /K m , or both, is likely. Because a similar increase in ARGII protein abundance, v i and V max /K m , of arginase activity was seen in MSPH, higher arginase activity resulting from higher ARGII protein abundance in MSPH compared with MPH is feasible. In addition, Eadie-Hofstee plot of arginase saturable activity was linear, suggesting that mainly, if not only, ARGII activity could account for urea generation in HUVEC.
Vascular Reactivity and the l-Arginine/NO Pathway
L-NAME (NOS inhibitor) reduced CGRP dilation in the absence of BEC in MPH or MSPH. Thus, NOS activity was required for CGRP dilation in umbilical veins. Because NO-dependent CGRP dilation in MPH was ≈5.5-fold compared with MSPH, NOS activity was probably reduced to a greater extent in MSPH compared with MPH. Interestingly, CGRP dilation was abolished by L-NAME+BEC, suggesting that CGRP effect is potentiated after arginases inhibition in vessels from either conditions. Because HUVEC from MSPH exhibit unaltered eNOS protein abundance compared with MPH, lower CGRP dilation in MSPH may result from reduced NOS activity. The reduced eNOS activity in MSPH could result from larger reduction of eNOS activationassociated Ser 1177 phosphorylation, 30, 38 compared with a less pronounced reduction of eNOS inactivation-associated Thr 495 phosphorylation. 29, 39 Furthermore, a larger eNOS inhibition should be expected in MSPH because increased eNOS activity caused by reduced inhibitory Thr 495 phosphorylation could be a phenomenon that will counteract eNOS inactivation as a result of a lower Ser 1177 phosphorylation-dependent stimulation of this enzyme. It is known that eNOS activity is reduced by the semiessential neutral amino acid l-glutamine likely because of l-citrulline depletion in HUVEC. 40 Thus, an alternative mechanism for eNOS inhibition could be increased fetal blood l-glutamine level in MSPH. However, young adult female pigs selected genetically for low-or high-plasma TCh exhibit similar umbilical vein blood l-glutamine levels. 41 Thus, because MSPH associates with reduced eNOS activity in HUVEC and because TCh, HDL-C, and triglycerides in human umbilical vein blood were unaltered by MSPH, it is possible that reduced eNOS activity was not caused by a potential detrimental effect of circulating l-glutamine in the human fetal endothelium. Inhibition of arginase activity was associated with activation of eNOS in HUVEC from MPH or MSPH. In MSPH, it could result from a dual phenomenon involving higher Ser 1177 phosphorylation-associated activation in addition to lower Thr 495 phosphorylation-associated inactivation of eNOS. The same could happen in MPH but at lower magnitude compared with MSPH because BEC-increased NOS activity in MSPH was only ≈1.9-fold than that in MPH. Thus, a metabolically less efficient eNOS caused by a higher arginase activity in HUVEC from MSPH compared with MPH is likely. ARGII metabolizes l-arginine, the substrate for eNOS in HUVEC 29 and other cell types, 4, 21, 42 suggesting that a lower l-arginine bioavailability could result in reduced eNOS activity in MSPH. Because l-arginine uptake is required for eNOS activity in HUVEC, 30 a reduced uptake and further delivery of this amino acid to eNOS could occur in MSPH. 43, 44 Because HUVEC from MSPH exhibit higher V max and V max /K m for l-arginine transport compared with MPH, a reduced eNOS activity caused by other than reduced l-arginine transport mechanism is likely. BEC caused an increase of l-arginine transport and NOS activity in cells from MPH or MSPH thus l-arginine was apparently preferentially metabolized via arginases rather than eNOS. This is likely because the V max /K m of arginase activity in HUVEC from MPH or MSPH is ≈5.5× that for eNOS, agreeing with reports in bovine aortic endothelium. 45 In addition, V max /K m for arginase activity is reported as ≈1000× that for NOS activity in other cell types. 45 Other studies report that hCAT-1 activity is required for eNOS function in endothelium. 43, 44 Our results suggest that this isoform is likely involved in the alterations associated with MSPH because the apparent K m values are within the range of the reported values for this transport activity. In addition, because the hCAT-2A/B activity associates with activity of the inducible NOS isoform in most mammalian cells and because protein abundance of these transporters was unaltered in MSPH, it is likely that they will not play a role in MSPH-increased l-arginine transport Human umbilical vein endothelial cells were isolated from term pregnancies where women exhibited maternal physiological (MPH, <280 mg/dL TCh) or supraphysiological hypercholesterolemia (MSPH, ≥280 mg/dL TCh) in pregnancy (see Materials and Methods). Arginases activity corresponds to urea formation inhibited by 20 μmol/L BEC (10 min). Saturable l-arginine transport was derived from the overall l-arginine transport (see Methods) in cells incubated in the absence (-) in HUVEC. Furthermore, MSPH-associated alterations in endothelial function could result from changes in l-arginine transport activity rather than altered umbilical vein blood or maternal blood l-arginine concentration. This is supported by reports showing that altered maternal or fetal blood TCh does not alter umbilical vein and maternal blood l-arginine concentration. 46, 47 In summary, MSPH is a pathological condition of the mother that associates with reduced human umbilical vein dilation compared with pregnant women coursing with a physiological increase in plasma cholesterol. We established a cut-off point for MSPH on the basis of umbilical vein alterations described in this study. HUVEC from MSPH exhibit reduced endothelial l-arginine/NO (likely eNOS derived) but increased arginases (likely ARGII)/urea signaling pathways compared with MPH. Arginases inhibition restored eNOS activity and drove increased l-arginine transport (likely via hCAT-1) in cells from MPH and MSPH. The results show that HUVEC dysfunction in MSPH has consequences on umbilical vein reactivity, a phenomenon that could be a major complication for the growing fetus. Although fetal cholesterol levels were normal at term birth, maternal hypercholesterolemia may influence fetal cholesterol levels at early stages of pregnancy. It is, therefore, possible that the altered endothelial function and vascular responses observed at birth reflect earlier pathogenic programming by MSPH. Alternatively, pathogenic effects may result from metabolic products other than TCh that are increased in MSPH and are capable of crossing the placental barrier. Considering that MSPH treatment or prevention studies are necessary to establish a causal effect, the results here reported highlight the possibility that alterations of umbilical vein function associated with increased maternal cholesterol levels will likely begins in prenatal life.
